PUBLICATIONS

Data repository

Meta-Analysis and systematic review for gout therapeutics on serum uric acid (SUA) lowering

Mild phenotype and late onset in molybdenum cofactor deficiency: a novel prevalent variant in MOCS2 gene in Roma, submitted (In Progress)

Disruption of G-quadruplex formation in the regulatory elements are highly correlated with the cancer gene expression, submitted (In Progress)

Recent Publications

R Cachau, S Shahsavari, SK Cho The in silico evaluation of important GLUT9 residue for uric acid transport based on renal hypouricemia type 2. Chemico-Biological Interactions 2023 Mar 1;373:110378 (Corresponding author)

Jenkins C, Hwang J Kopp JB, Winker CA, Cho SK. Review of urate-lowering therapeutics: From the past to the future. Frontiers Pharmacology, in press (2022)

Lee, Y., Hwang, J., Desai, S. H., Li, X., Jenkins, C., Kopp, J. B., Winkler C. A.,& Cho, S. K. (2022). Efficacy of Xanthine Oxidase Inhibitors in Lowering Serum Uric Acid in Chronic Kidney Disease: A Systematic Review and Meta-Analysis. JCM 2022, 11(9) 3468

Yoon, J., Cachau, R., David, V. A., Thompson, M., Jung, W., Jee, S. H., & Cho, S. K. (2021). Characterization of a Compound Heterozygous SLC2A9 Mutation That Causes Hypouricemia. Biomedicines, 9(9), 1172.

Cho, S.K., Kim B., Myung W., Chang Y, Ryu S., Kim H-N, Kim H-L, Kuo P-H,, Winkler CA, & Won H-H (2020). Polygenic analysis of the effect of common and low-frequency genetic variants on serum uric acid levels in Korean individuals. Sci Rep. 2020 Jun 8;10:9179

~ 2019

Cha DH, Gee HY, Cachau R, Choi JM, Park D, Jee SH, Ryu S, Kim KK, Won HH, Limou S, Myung W, Winkler CA, & Cho, S.K.(2019) “Contribution of SLC22A12 on hypouricemia and its clinical significance for screening purposes” Sci Rep. 2019 Oct 7;9:14360 (Corresponding author)

Cho, S.K., Winkler CA, Lee S-J, Chang Y, & Ryu S. (2019). “The Prevalence of Hyperuricemia Sharply Increases from the Late Menopausal Transition Stage in Middle-Aged Women” J Clin Med. 2019 8, 296

Cho, Sung Kweon, et al. “U‐shaped association between serum uric acid level and risk of mortality: a cohort study.” Arthritis & Rheumatology 70.7 (2018): 1122-1132.

Lee W.S, Shim S.R, Lee S.Y, Yoo J-S, & Cho, S.K. (2018). “Preclinical Pharmacokinetics, Interspecies Scaling, and Pharmacokinetics of a Phase 1 Clinical Trial of Tanibirumab, a Fully Human Monoclonal Antibody against Vascular Endothelial Growth Factor 2” Drug Design, Development and Therapy 2018:12 495–504

Cho S., Son H, & Cho, S.K. (2018). “The 120min oral glucose tolerance test (OGTT) is sufficient for the evaluation of metformin’s glucose lowering effect in healthy volunteers” Int J Clin Pharmacol Ther. 2018 Mar;56(3):15115

Nam D.C, Ha Y.M, Park M. K, & Cho, S.K. (2016). “The rs662 polymorphism of paraoxonase 1 affects the difference in the inhibition of butyrylcholinesterase activity by organophosphorus pesticides in human blood” Int J Clin Pharmacol Ther. 2016 Aug; 54(8): 622-7

Cho, S.K. & Chung J.Y. (2016). “The MATE1 rs2289669 polymorphism affects the renal clearance of metformin following ranitidine treatment” Int J Clin Pharmacol Ther. 2016 Apr;54(4):253-62

Cho, S.K. S, Kim, Chung J.Y, & S.H. Jee. (2015). “Discovery of URAT1 SNPs and association between serum uric acid levels and URAT1.” BMJ Open. 2015 Nov 24;5(11): e009360.

Cho, S.K. Kim CO, Park ES, & Chung JY (2014). “Verapamil decreases the glucose-lowering effect of metformin in healthy volunteers.” Br J Clin Pharmacol. 2014 Dec;78(6):1426-32

Cho, S.K. H Oh, SH Hong, MS Park, & JY Chung (2014). “Pregnane X Receptor agonist Increases the Expression Levels of the Plasma Membrane Monoamine Transporter” Translational and Clinical Pharmacology 2014;22(1):19-21

Chung, J.Y. and Cho, S.K. Kim TH, Kim KH, Jang GH, Kim CO, Park EM, Cho JY, Jang IJ, & Choi JH. (2013). “Functional characterization of MATE2-K genetic variants and their effects on metformin pharmacokinetics.” Pharmacogenet Genomics. 2013 Jul;23(7):365-73 (Co-first)

Cho, S. K., Oh, ES, Park, K, Park, MS, & Chung, JY (2012). “UGT1A3*2 polymorphism affects atorvastatin lactonization and lipid lowering effect in healthy volunteers” Pharmacogenet Genomics. 2012 Aug;22(8):598-605

Cho, S. K., CO Kim, SH Yu, ES Oh, SB Jang, YS Park, K Cho, & J-Y Chung (2012). “Bioequivalence and Dose Proportionality of Olmesartan Medoxomil Formulations” J Korean Soc Clin Pharmacol Ther 2012;20(2):145-154

Cho, S. K., Yoon JS, Lee MG, Lee DH, Lim LA, Park K, Park MS, & Chung JY. (2011). “Rifampin Enhances the Glucose-Lowering Effect of Metformin and Increases OCT1 mRNA Levels in Healthy Participants.” Clinical pharmacology & therapeutics. 2011 89(3): 416-421.